Skip to main content
. 2019 Apr 15;74(7):1984–1991. doi: 10.1093/jac/dkz076

Table 2.

Pharmacokinetic parameters for children administered BPG for RHD prophylaxis

BMI <25 kg/m2 (n = 10), median (IQR) (range) BMI ≥25 kg/m2 (n = 8), median (IQR) (range)
t ½, abs-1 (days) 0.35 (0.29–1.60) (0.13–1.95) 0.30 (0.26–0.63) (0.17–2.13)
t ½, abs-2 (days) 9.8 (4.7–12.8) (3.1–26.5) 20.3 (13.4–23.8) (4.7–38.4)
C min (μg/L) 5.64 (1.31–9.76) (0.43–11.9) 7.15 (6.27–9.11) (0.01–17.0)
C max (μg/L) 34.8 (29.1–52.4) (21.6–68.4) 19.8 (17.1–22.1) (8.99–38.1)
T max (h) 45.6 (36.3–72.0) (18.7–102) 43.0 (39.1–59.3) (23.3–156)
Time >0.02 mg/L (days) 9.75 (7.75–12.0) (3.50–18.5) 0 (0–4.31) (0–23.3)
Time >0.02 mg/L (%) 35 (27–42) (12–67) 0 (0–15) (0–80)
Time >0.01 mg/L (days) 19.0 (15.3–26.5) (12.3–32.4) 18.5 (15.8–25.2) (0–37.26)
Time >0.01 mg/L (%) 65 (53–95) (29–100) 69 (55–91) (0–100)